SC 13D/A 1 sc13daopthal121605.txt SCHEDULE 13D/A (AMENDMENT NO. 6) ----------------------------- OMB APPROVAL ----------------------------- OMB Number 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response ....... 11 ----------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 6) Ophthalmic Imaging Systems -------------------------------------------------------- (Name of Issuer) Common Stock, no par value -------------------------------------------------------- (Title of Class of Securities) 683737 ------------------ (CUSIP Number) Medivision Medical Imaging Ltd. Henry I. Rothman, Esq. P.O. Box 45, Industrial Park Troutman Sanders LLP Yokneam Elit The Chrysler Building 20692 Israel 405 Lexington Avenue Attn: Noam Allon New York, New York 10174 972-4-9894884 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 16, 2005 --------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ] CUSIP No. 683737 13D Page 2 of 4 Pages -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). MediVision Medical Imaging Ltd. -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC Use Only -------------------------------------------------------------------------------- 4. Source of Funds: BK -------------------------------------------------------------------------------- 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) [ ] -------------------------------------------------------------------------------- 6. Citizenship or Place of Organization Israel -------------------------------------------------------------------------------- Number of 7. Sole Voting Power 10,420,851 Shares Bene- ------------------------------------------------------ ficially Owned 8. Shared Voting Power -0- By Each ------------------------------------------------------ Reporting 9. Sole Dispositive Power 10,420,851 Person With ------------------------------------------------------ 10. Shared Dispositive Power -0- -------------------------------------------------------------------------------- 11. Aggregate Amount Beneficially Owned by Each Reporting Person 10,420,851 -------------------------------------------------------------------------------- 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ] -------------------------------------------------------------------------------- 13. Percent of Class Represented by Amount in Row (11) 67.2% -------------------------------------------------------------------------------- 14. Type of Reporting Person (See Instructions) CO -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! AMENDMENT NO. 6 TO SCHEDULE 13D This filing constitutes Amendment No. 6 to the Statement on Schedule 13D (the "Schedule 13D") filed on behalf of MediVision Medical Imaging Ltd. ("MediVision") with respect to the shares of common stock no par value (the "Shares") of Ophthalmic Imaging Systems ("OIS"). Except as to Item 5, no change has occurred with respect to the answer to any items of this Schedule 13D from information last reported. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. On December 16, 2005, MediVision sold 310,000 shares of common stock, no par value, at $1.45 per share to Bard Associates, Inc. Prior to this sale, MediVision owned 10,730,851 Shares. Presently, MediVision owns 10,420,851 Shares or 67.2% of the issued and outstanding Shares. SIGNATURE After reasonable inquiry and to the best of our knowledge and belief, the Reporting Person certifies that the information set forth in this statement is true, complete and correct. Dated: December 16, 2005 MEDIVISION MEDICAL IMAGING LTD. By: /s/ Noam Allon ------------------------------------- Name: Noam Allon Title: President and CEO